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Abstract
Background: Presumptive treatment of malaria is common practice in malaria endemic resource-limited settings.
With the changing epidemiology of malaria and the introduction of artemisinin-based combination therapy (ACT),
there is increasing need for parasite-based malaria case management to prevent unnecessary use of anti-malarial
medicines, improve patient care in parasite-positive patients and identify parasite-negative patients in whom
another diagnosis must be sought. Although parasitological confirmation by microscopy or alternatively by malaria
rapid diagnostic tests (RDTs) is recommended in all patients suspected of malaria before treatment, gaps remain in
the implementation of this policy in resource-limited settings. There is need to evaluate the use of RDTs among
highly active anti-retroviral therapy (HAART)-treated people living with HIV (PLHIV).
Methods: Within an urban prospective observational research cohort of 559 PLHIV initiated on HAART and
cotrimoxazole prophylaxis between April, 2004 and April, 2005, 128 patients with sustained HIV-RNA viral load <
400 copies/ml for four years were evaluated, in a cross-sectional study, for asymptomatic malaria infection using a
histidine-rich protein-2 (HRP-2) RDT to detect Plasmodium falciparum antigen in peripheral blood. Patients with
positive RDT results had microscopy performed to determine the parasite densities and were followed for clinical
signs and symptoms during the subsequent six months.
Results: Of the 128 asymptomatic patients screened, only 5 (4%) had asymptomatic P. falciparum antigenaemia. All
the patients with positive HRP2 RDT results showed malaria parasites on thick film with parasite densities ranging
from 02-15 malaria parasites per high power field. None of the patients with positive RDT results reported signs
and symptoms of malaria infection during the subsequent six months.
Conclusions: In an urban area of low to moderate stable malaria transmission, there was low HRP2 P. falciparum
antigenaemia among PLHIV after long-term HAART and cotrimoxazole prophylaxis. Parasite-based malaria diagnosis
(PMD) is recommended among PLHIV that are on long-term anti-retroviral therapy. RDTs should be utilized to
expand PMD in similar settings where microscopy is unavailable.
Background
Presumptive treatment of malaria is common practice
among individuals presenting with fever in malaria
endemic settings including people living with HIV/AIDS
(PLHIV) [1-3]. With the changing epidemiology of
malaria and the introduction of artemisinin-based com-
bination therapy (ACT), there is increasing need for
parasite-based malaria case management as a strategy to
prevent unnecessary use of anti-malarials, improve
patient care in parasite-positive patients and identify
parasite-negative patients in whom another diagnosis
must be sought [4]. Although prompt parasitological
confirmation by microscopy or alternatively by malaria
rapid diagnostic tests (RDTs) is recommended in all
patients suspected of malaria before treatment, gaps
remain in the implementation of this policy in resource-
limited settings [1,5,6].
HIV-1 infection has been associated with an increased
incidence of malaria, and more severe disease [3,7-9].
However, a combination of co-trimoxazole, anti-retroviral
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reduced the frequency of malaria in adults with HIV in a
rural malaria endemic community [2,8]. There is need to
evaluate the use of RDTs among highly active anti-retro-
viral therapy (HAART)-treated HIV-infected individuals.
RDTs have been shown to be over 95% sensitive in detect-
ing Plasmodium falciparum antigenaemia [5,10], even in
HIV/AIDS rural populations [11,12]. The aim of this study
was to determine the prevalence of asymptomatic malaria
among HAART-treated patients in an urban malaria
meso-endemic setting. The findings emphasize, to HIV/
AIDS clinicians, the utility of parasitological-based diagno-
sis versus presumptive treatment of malaria within HIV
treatment programs in sub-Saharan Africa (SSA). This
study contributes to the understanding of the potential
utility of malaria diagnosis including RDTs among PLHIV
in the region.
Methods
Study setting and participants
Between April, 2004 and April, 2005, 559 consecutive
HAART-naïve HIV-infected adults, were initiated on
HAART and enrolled into a prospective observational
research cohort as previously described [13] at the Infec-
tious Diseases Institute (IDI) in Kampala, the capital city
of Uganda. Patients were initiated on first-line HAART at
CD4 counts ≤ 200 cells/μL according to Ugandan guide-
lines for HAART initiation at the time. Drugs were pro-
vided through the Global Fund (a generic combined
formulation of stavudine [d4T}, lamivudine [3TC], and
nevirapine [NVP] and the US President’s Emergency Plan
for AIDS Relief (a combined formulation of zidovudine
[ZDV] and 3TC plus efavirenz [EFZ] or nevirapine [NVP].
Patients with toxicity to ZDV were changed to tenofovir
[TDF]. All patients received cotrimoxazole (or dapsone)
prophylaxis according to the national policy to provide
cotrimoxazole to all PLHIV. Adherence to HAART was
encouraged by at least three individual and group counsel-
ing sessions. Patients were reviewed monthly by the study
physicians that evaluated among others; adherence to
medication, toxicities and acute infections. HIV RNA viral
loads, complete blood counts and CD4 counts were mea-
sured at six monthly intervals. In addition to cotrimoxa-
zole prophylaxis, all patients receive insecticide-treated
bed nets (ITNs) and malaria prevention education as well
as prompt treatment of fever symptoms at the study clinic.
The patients do not use home-based anti-malarial therapy
however they are encouraged to call and/or walk to the
study clinic whenever ill. Anti-malarial prescriptions are
based on both clinical and microscopy findings and RDTs
are not used routinely.
After four years of follow up on HAART, 252/559
(45%) patients had sustained HIV-RNA viral suppression
defined as HIV-RNA levels < 400 copies/ml within the
four years of anti-retroviral therapy. Of these, 41 were
excluded due to the following reasons; death (n = 25),
lost to follow-up (n = 5), voluntary request to transfer
to and voluntary termination from the study (n = 11).
Of the remaining 211 patients with chronic HIV infec-
tion successfully suppressed on HAART, 128 patients
were selected by systematic random sampling (see
Figure 1). Every other patient was selected from the reg-
ister of patients with sustained HIV-RNA viral suppres-
sion plus an additional 20% to cater for non-response
and loss to follow up. All study participants provided
written informed consented and the study was approved
by the Uganda National Council For Science and Tech-
nology (UNCST).
In a cross-sectional study to evaluate the prevalence of
asymptomatic malaria among HAART-treated patients,
an RDT was performed for each participant using the P.
falciparum immuno-chromatographic test (ICT); that
detects the P. falciparum-specific antigen, histidine-rich
protein-2 (HRP-2). The commercially available RDT kit
at Uganda health marketing group (UHMG) was used;
Diagnostics malaria P. f
® cassettes (SSA Diagnostics and
Biotech systems, Verna industry estate, Verna, Goa
403722 India) Lot number S21004, manufactured Sep-
tember 2009 and expire August 2011. The manufac-
turer’s storage temperature specifications (4-30°C) were
maintained and monitored.
Laboratory activities
Participants underwent aseptic venipuncture for collec-
tion of 3-5 ml of EDTA-anticoagulated whole blood. The
haemoglobin level, total white blood cell count and dif-
ferential counts and the malaria RDTs were performed
within 4-6 hrs of sample collection. A drop (5 μl) of
whole blood was dropped into the smaller well at one
end of the cassette. Five (5) drops of clearing buffer were
dropped into the other well. Results were reported within
15 minutes after adding buffer. Appearance of the control
band showed that the blood had migrated along the test
strip membrane correctly (negative control). A RDT
result was interpreted as positive when both the test line
and control line showed pink, negative when only the
control line showed pink or invalid when the control line
did not appear regardless of the test line.
Thick film microscopy was performed, by a trained
laboratory technologist, for all the positive HRP2 RDT
results. Blood smears were stained with 10% Giemsa for
30 minutes. Thick smears were examined for parasites
including gametocytes and parasite densities were deter-
mined by counting the number of asexual parasites per
200 white blood cells (WBC), or per 500 WBC if the
parasite count was less than 10 parasites per 200 WBC,
assuming a WBC count of 8,000/μl. Microscopy was not
performed for negative RDT results considering the
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and the fact that the participants did not have symp-
toms of malaria illness. Positive thick film results were
defined by the presence of one or more confirmed
malaria parasite. Participants with positive RDT results
were not given anti-malarial drugs considering that they
had no symptoms of illness plus the fact that it is not a
national policy to treat asymptomatic P. falciparum
infection. However, these patients were followed up
weekly for the first month and monthly for the next five
months to determine if they developed signs and symp-
toms of malaria infection.
Results
Majority, 94/128 (73%) of the patients were female and
the median age was 38 [Interquartile range (IQR), 33-
44] years. After four years of HAART with sustained
viral suppression, the median CD4 count was 327 (IQR,
247-454) cells/μL. Haematological parameters (haemo-
globin, total white cell count and differential counts)
were within the normal ranges (see Table 1). Of the 128
patients tested with an RDT, only 5 (4%) had P. falci-
parum antigenaemia. All the patients reported no his-
tory of anti-malarial medication within the two months
preceding this study. Thick films for patients with posi-
tive RDT results showed malaria parasites densities ran-
ging from 02-15 malaria parasites per high power field
(hpf) (Table 2). None of the patients with positive RDT
results reported signs and symptoms of malaria infection
during the subsequent six months.
Discussion
This study showed a low prevalence (4%) of asympto-
matic P. falciparum parasitemia among HAART-treated
patients with sustained HIV-RNA viral suppression. The
malaria parasite prevalence among HIV patients in this
559 initiated ART 
  69% female 
  Median age 38 (33-44) yrs 
  51% had baseline CD4 count <100 cells/ ȝl 
 74%  initiated  D4T+3TC+NVP & 26% initiated ZDV+3TC+EFV 
252 has sustained viral suppression up to 4 years 
25 died (15-HIV/AIDS-related deaths, 6 –other medical 
 Illnesses, 4 cause of death cannot be 
determined) 
7 transferred out to other ART centers 
5 lost to follow up 
4 withdrew consent to participate in the research cohort 
0 patients with a reported opportunistic infection (s) 6 
months prior to the study 
128 patients systematically selected 
Complete blood count (CBC) and rapid 
diagnostic test (RDT) for malaria were 
 performed 
211 patients were 
eligible for current study 
Figure 1 Profile of patients on anti-retroviral therapy and cotrimoxazole within the Infectious Disease Research cohort.
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lence of 7.4% among under-five children as reported in
the 2009 malaria indicator survey [14]. It is important to
note that the latter result is not directly comparable
with the current study among HAART & cotrimoxa-
zole-treated adults however it is one of the indicators of
malaria endemicity in this urban setting. The findings of
this study are consistent with previous reports of low
prevalence of malaria infections among successfully trea-
ted HIV-infected adults [2,8,15]. All the study partici-
pants had received ongoing cotimoxazole prophylaxis,
ITNs and malaria prevention education as recom-
mended by the HIV/AIDS treatment guidelines [16].
Results from this study imply that although HIV-
infected individuals were previously considered among
the special risk groups for malaria infections [3,4], there
is need to re-evaluate the risk of malaria infection after
long-term successful HAART. The authors recommend
parasite-based diagnosis of malaria in similar settings in
order to avoid over-prescription of anti-malarial medi-
cines. However, the choice between RDTs and micro-
scopy to implement this depends on local circumstances
that include the skills available, patient load, epidemiol-
ogy of malaria and the possible use of microscopy for
the diagnosis of other diseases.
The use of the simple rapid tests to detect malaria
antigenaemia among PLHIV emphasizes the utility of
RDTs in parasite-based malaria diagnosis (PMD) in this
population. The findings of this study will contribute to
the implementation of RDTs for PMD among PLHIV in
areas where microscopy is not accessible [4]. Moreover,
use of RDT results to guide anti-malarial therapy
is likely to reduce anti-malarial drug costs due to over-
prescription [6,17]. With the introduction of artemesi-
nin-based combination therapy (ACT) [18] coupled with
the high pill burden among HIV-infected individuals on
HAART, cotrimoxazole and treatment for other co-mor-
bidities, presumptive treatment of malaria is increasingly
becoming clinically and economically inappropriate [1].
With the declining incidence of malaria in Africa [1],
plus the results from this study, there is need to scale
up parasite-based malaria diagnosis in successfully trea-
ted HIV-infected adults in areas of low to moderate
stable malaria transmission. Similarly, there is need to
evaluate the utility of RDTs among successfully treated
HIV-infected adults with febrile illnesses.
During follow up, none of the patients with asympto-
matic parasitaemia reported development of clinical
signs and symptoms of malaria infection during the sub-
s e q u e n ts i xm o n t h s .I ti so fi n t e r e s tt on o t et h a tH I V -
infected adults did not develop clinical symptoms of
malaria despite the increased risk of malaria infections
associated with the HIV-associated immune suppression
Table 1 Characteristics of 128 patients with sustained viral suppression after 4 years of highly active antiretroviral
therapy (HAART) in an urban African cohort
Variable Parameters 4 years after ART initiation
Age (yrs) 38 (33-44)
Female gender n (%) 94 (73%)
Body mass index (BMI), median (IQR) 22 (20-25)
Baseline CD4 count (cells/μl), median (IQR) 102 (38-167)
CD4 count after 4 years of ART (cells/μl) median (IQR) 327 (247-454)
HAART regimen
Stavudine-Lamividine-Nevirapine/Efavirenz [n (%)] 55 (43%)
Zidovidine-Lamivudine- Nevirapine/Efavirenz [n (%)] 67 (52%)
Tenofovir-Emitricitabine-Nevirapine/Efavirenz [n (%)] 6 (5%)
Haemogram
Total white count, median (IQR) 4429 (3300-5040)
Percentage neutrophils, median (IQR) 44 (37-53)
Percentage lymphocytes, median (IQR) 43(32-47)
Percentage eosinophils, median (IQR) 2 (1-6)
Haemoglobin (mg/dl), median (IQR) 14 (12-15)
Table 2 Microscopy results for 5/128 (4%)* asymptomatic
patients with Histidine-rich proteins-2 (HRP-2) positive
antigenaemia after 4 years of successful highly active
antiretroviral therapy (HAART) in an urban African cohort
Patient
number







*These patients reported no history of recent treatment of malaria in the
previous two months. During follow up, none of the five patients developed
clinical symptoms and signs of malaria during the subsequent six months.
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fact that the parasite densities were low since the devel-
opment of clinical symptoms correlates positively with
parasite densities [20]. It is also possible that long-term
HAART restores the hosts’ ability to control the infec-
tion. Similarly, the authors postulate that long-term
cotrimoxazole prophylaxis could contribute to the hosts’
response to the asymptomatic P. falciparum parasitae-
mia. However, there is need to study the recovery of the
host’s immunological responses to P. falciparum infec-
tion among PLHIV in the setting of long-term HAART
and cotrimoxazole prophylaxis.
Conclusion
In an urban area of low to moderate stable malaria
transmission, there was low HRP2 P. falciparum antige-
naemia among PLHIV after long-term successful
HAART and cotrimoxazole prophylaxis. Parasite-based
malaria diagnosis (PMD) is recommended among
PLHIV that are on successful long-term anti-retroviral
therapy. RDTs should be utilized to expand the use of
PMD in similar settings where microscopy is
unavailable.
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